Mpox surveillance

Please be aware unlinked community transmission is occurring and clinicians are encouraged to offer vaccination to all eligible priority populations. ATAGI now recommends pre-travel vaccination for anyone (regardless of sexual orientation or gender identity) who may undertake sexual risk activities during travel to countries with transmission of clade I mpox.

Queensland Health publishes regular surveillance reports for mpox cases.

Last updated date: 21 January 2025

Updated ATAGI Clinical Guidance on the use of vaccines for prevention of mpox is now available.

  • ATAGI now recommends pre-travel vaccination for anyone (regardless of sexual orientation or gender identity) who may undertake sexual risk activities during travel to countries with transmission of clade I mpox.
  • There is good supply of mpox vaccine in Queensland and it is available free of charge to all Queensland Health Immunisation Program (QHIP) registered vaccine service providers. Email QHIP-ADMIN@health.qld.gov.au to order mpox vaccine (or register if not already registered).
  • Vaccine providers can be found at mpox (monkeypox) vaccination centres
  • Clinicians are encouraged to offer vaccination to all eligible priority populations and to follow-up people who have not had their second vaccination at least 28 days following their first vaccine. Eligibility criteria can be found at mpox (previously known as monkeypox)

The updated mpox National Guidelines for Public Health Units has been published.

Since 1 January 2024, there have been 128 confirmed cases of mpox notified in Queensland . Of these:

  • Most cases were acquired in Australia, with the primary transmission route being sexual transmission between men who have sex with men.

Cases have been identified in eight Hospital and Health Service catchments: Darling Downs, Gold Coast, Metro North, Metro South, Sunshine Coast, Townsville, West Moreton and Wide Bay.

Mpox cases graph 5 November 2024

Figure 1. Mpox cases notified in Queensland since 1 January 2024, as of  21 January 2025.

Table 1. Characteristics of mpox cases notified in Queensland since 1 January 2024, as of 21 January 2025.
NB: the “overseas” cases were in two overseas visitors to Queensland, who acquired mpox in Queensland.

Characteristic
N = 1281
Median age (range)
36 (18, 82)
Sex 
    Female
2 / 128    (1.6%)
    Male
125 /  128 (98%)
    Other
1 / 128    (0.8%)
First Nations Status 
    First Nations
4 / 128 (3.1%)
    Other Queenslanders
122 / 128 (95%)
    Unknown
2 / 128  (1.6%)
HHS of residence 
    Darling Downs
5 / 128  (3.9%)
    Gold Coast
28 / 128 (22%)
    Metro North
50 / 128 (39%)
    Metro South
21 / 128 (16%)
    Overseas
2 / 128  (1.6%)
    Sunshine Coast
10 / 128 (7.8%)
    Townsville
1 / 128 (0.8%)
    West Moreton
10 / 128 (7.8%)
    Wide Bay
1 / 128  (0.8%)
Vaccination status prior to exposure 
    Fully vaccinated
33 / 128 (26%)
    Not vaccinated
82 /  128 (64%)
    Partially vaccinated
5 / 128 (3.9%)
    Unknown
8 / 128 (6.3%)
HIV coinfection 
    HIV negative
115 / 128 (90%)
    HIV positive
13 / 128 (10%)
Place of acquisition 
    Australia
124 / 128 (97%)
    Unknown/Under investigation
4 / 128  (3.1%)
Transmission mode 
    Sexual transmission
127 / 128 (99%)
    Unknown/Under investigation
1 / 128 (0.8%)
Sexual exposure type 
    Both sexes
2 / 128 (1.6%)
    Opposite sex
4 / 128 (3.1%)
    Same sex
119 / 128 (93%)
    Unknown/Under investigation
3 / 128 (2.3%)

1 Median (Min, Max); n / N (%)

For a national mpox epidemiological snapshot, refer to the National Communicable Disease Surveillance Dashboard: https://nindss.health.gov.au/pbi-dashboard/

Additional information

The mpox fact sheet on the Health Conditions Directory:

Fact sheets for cases and contacts:

Primary Care clinicians are encouraged to access their local HealthPathways platform for further information.

Last updated: 21 January 2025